Medline Inc. MDLN NASDAQ · Healthcare · United States
$39.47 -1.28% -$0.51
Summary
41 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $2.00B in the last fiscal year, 5.8% of its market value.
- Analysts expect revenue to grow by 10% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 3.9 years of operating profit.
- Out of every 100 USD of revenue, only 1.8 USD is left as net profit.
- It earns only 3.7 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 61.5 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 10%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 75 USD
- Sales and administration 19 USD
- Taxes and other 3.8 USD
- Net profit 1.8 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 1.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 17
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $44.11 is 12% above today's price. 89% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.